Climb Bio (NASDAQ:CLYM) Price Target Raised to $25.00

Climb Bio (NASDAQ:CLYM) had its price objective lifted by Robert W. Baird from $21.00 to $25.00 in a research note released on Thursday morning, Marketbeat reports. The brokerage currently has an outperform rating on the stock.

Several other brokerages also recently weighed in on CLYM. Royal Bank Of Canada started coverage on Climb Bio in a report on Monday, August 3rd. They issued an “outperform” rating and a $23.00 price target for the company. Truist Financial upped their price objective on shares of Climb Bio from $17.00 to $25.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wall Street Zen raised shares of Climb Bio from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. BTIG Research lifted their target price on shares of Climb Bio from $20.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.92.

Climb Bio Price Performance

Climb Bio stock opened at $15.52 on Thursday. The stock has a market capitalization of $891.47 million, a price-to-earnings ratio of -18.70 and a beta of 0.09. Climb Bio has a 1-year low of $1.54 and a 1-year high of $18.33. The business has a fifty day moving average price of $14.04 and a 200-day moving average price of $10.79.

Climb Bio (NASDAQ:CLYM) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.03. On average, equities research analysts anticipate that Climb Bio will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of Climb Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. MPM Bioimpact LLC purchased a new stake in Climb Bio during the 4th quarter valued at about $10,686,000. BlackRock Inc. purchased a new position in shares of Climb Bio in the second quarter worth about $30,708,000. Braidwell LP raised its stake in shares of Climb Bio by 102.6% in the second quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock worth $40,411,000 after purchasing an additional 1,569,352 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Climb Bio by 265.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock worth $7,695,000 after purchasing an additional 1,396,722 shares during the last quarter. Finally, ADAR1 Capital Management LLC lifted its holdings in shares of Climb Bio by 972.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock worth $5,730,000 after purchasing an additional 1,298,945 shares during the period. Institutional investors and hedge funds own 69.76% of the company’s stock.

More Climb Bio News

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Encouraging CLYM116 data: Climb Bio reported that a single 320 mg dose of CLYM116 produced an approximately 29-day half-life, near-complete APRIL suppression, and 60%–75% reductions in IgA and Gd-IgA1 through 12 weeks. The drug was generally well tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia reported. The data support convenient once-every-12-weeks dosing for IgA nephropathy. Climb Bio CLYM116 Phase 1 Data
• Positive Sentiment: Analyst targets moved substantially higher: B. Riley reaffirmed a Buy rating and raised its price target to $30 from $26. BTIG lifted its target to $32 from $20 and maintained a Buy rating, while Baird raised its target to $25 from $21 and rated the shares Outperform. These revisions indicate analysts see greater commercial and competitive potential for CLYM116.
• Positive Sentiment: Wedbush described the Phase 1 results as positive, while Oppenheimer said the data could demonstrate a competitive position in the IgA nephropathy market. Wedbush Climb Bio Phase 1 Analysis
• Neutral Sentiment: The Phase 2 NAVIGATE-2 trial is ongoing, with initial data expected in the first half of 2027 and a potential Phase 3 start in 2027. Those milestones could provide more meaningful evidence of efficacy, but they also leave significant clinical and execution risk ahead.
• Negative Sentiment: Despite the favorable safety and biomarker results, reports noted that the stock slipped as investors digested the early-stage nature of the data. Phase 1 results do not establish that CLYM116 improves patient outcomes, and the shares’ large prior rally may be encouraging some profit-taking or demanding stronger evidence before advancing further. Climb Bio Slips After Early-Stage Trial Data

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.